The Total i3+3 (Ti3+3) Design for Assessing Multiple Types and Grades of Toxicity in Phase I Trials
The New England Journal of Statistics in Data Science · 2024
DOI: 10.51387/22-nejsds7 ↗Kurz gefasst
Fachartikel in der Zeitschrift The New England Journal of Statistics in Data Science, 2024. Verfasst von Meizi Liu und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Phase I trials investigate the toxicity profile of a new treatment and identify the maximum tolerated dose for further evaluation. Most phase I trials use a binary dose-limiting toxicity endpoint to summarize the toxicity profile of a dose. In reality, reported toxicity information is much more abundant, including various types and grades of adverse events. Building upon the i3+3 design (Liu et al., 2020), we propose the Ti3+3 design, in which the letter “T” represents “total” toxicity. The proposed design takes into account multiple toxicity types and grades by computing the toxicity burden at each dose. The Ti3+3 design aims to achieve desirable operating characteristics using a simple statistics framework that utilizes“toxicity burden interval” (TBI). Simulation results show that Ti3+3 demonstrates comparable performance with existing more complex designs.
Zitieren
APA
Liu, M., Ji, Y., & Lin, J. (2024). The Total i3+3 (Ti3+3) Design for Assessing Multiple Types and Grades of Toxicity in Phase I Trials. The New England Journal of Statistics in Data Science. https://doi.org/10.51387/22-nejsds7
Vancouver
Liu M, Ji Y, Lin J. The Total i3+3 (Ti3+3) Design for Assessing Multiple Types and Grades of Toxicity in Phase I Trials. The New England Journal of Statistics in Data Science. 2024. doi:10.51387/22-nejsds7
BibTeX
@article{Liu2024,
author = {Liu, Meizi and Ji, Yuan and Lin, Ji},
title = {The Total i3+3 (Ti3+3) Design for Assessing Multiple Types and Grades of Toxicity in Phase I Trials},
journal = {The New England Journal of Statistics in Data Science},
year = {2024},
doi = {10.51387/22-nejsds7}
}
EUVIMED